| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1080/08977190400000833 |
| P698 | PubMed publication ID | 15621727 |
| P2093 | author name string | Kathryn C Zoon | |
| Jessica Hernandez | |||
| Joseph Bekisz | |||
| Hana Schmeisser | |||
| Neil D Goldman | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 243-51 | |
| P577 | publication date | 2004-12-01 | |
| P1433 | published in | Growth Factors Journal | Q5611728 |
| P1476 | title | Human interferons alpha, beta and omega | |
| P478 | volume | 22 |
| Q27491286 | A broad-spectrum antiviral targeting entry of enveloped viruses |
| Q40094086 | A novel role of the interferon-inducible protein IFI16 as inducer of proinflammatory molecules in endothelial cells |
| Q38506089 | Acetaminophen modulates the transcriptional response to recombinant interferon-beta |
| Q21261738 | Adult systemic cat scratch disease associated with therapy for hepatitis C |
| Q47612981 | An A/U-Rich Enhancer Region Is Required for High-Level Protein Secretion through the HlyA Type I Secretion System. |
| Q44684462 | An international comparability study to determine the sources of uncertainty associated with a non-competitive sandwich fluorescent ELISA. |
| Q26766115 | Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy |
| Q40272095 | Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1. |
| Q41625843 | Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector |
| Q34908895 | Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry |
| Q87924400 | Chronic Hepatitis C Infection in Children |
| Q60921469 | Clinical features of Sjögren's syndrome patients with autoantibodies against interferons |
| Q42979160 | Codelivery of PEG-IFN-alpha inhibits HCV DNA vaccine-induced T cell responses but not humoral responses in African green monkeys. |
| Q38216460 | Cytokine immunomodulation for the treatment of infectious diseases: lessons from primary immunodeficiencies |
| Q36382859 | Decreased Interferon Alpha/Beta Signature Associated with Human Lung Tumorigenesis |
| Q89935915 | Diverse effects of interferon alpha on the establishment and reversal of HIV latency |
| Q30251949 | Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials |
| Q57059911 | Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies |
| Q57465381 | Effect of Chemical Oxidation on the Higher Order Structure, Stability, Aggregation, and Biological Function of Interferon Alpha-2a: Role of Local Structural Changes Detected by 2D NMR |
| Q38613681 | Effect of type-I interferon on retroviruses. |
| Q38896327 | Effects of disruption of the nucleotide pattern in CRID element and Kozak sequence of interferon β on mRNA stability and protein production. |
| Q39565775 | Establishment of a stable CHO cell line with high level expression of recombinant porcine IFN-β. |
| Q38727522 | Future directions in bladder cancer immunotherapy: towards adaptive immunity |
| Q36141492 | HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha |
| Q36656715 | HIV-1 immunopathogenesis: how good interferon turns bad. |
| Q33804260 | High yield soluble bacterial expression and streamlined purification of recombinant human interferon α-2a. |
| Q38707618 | IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21. |
| Q35665366 | Identifying a role for Toll-like receptor 3 in the innate immune response to Chlamydia muridarum infection in murine oviduct epithelial cells |
| Q37895744 | Identifying innate immune pathways of the chicken may lead to new antiviral therapies |
| Q33703634 | Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens |
| Q38281748 | Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells |
| Q38973834 | Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. |
| Q28384715 | Interferon protects mice against inhalation anthrax |
| Q90568978 | Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma |
| Q45151753 | Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro |
| Q41928595 | Interferon-omega: Current status in clinical applications |
| Q33988567 | Interferons and their stimulated genes in the tumor microenvironment |
| Q35223673 | Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons |
| Q33389296 | Junín virus infection of human hematopoietic progenitors impairs in vitro proplatelet formation and platelet release via a bystander effect involving type I IFN signaling. |
| Q28483978 | Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α |
| Q29619805 | Mechanism of action of interferon and ribavirin in treatment of hepatitis C |
| Q34014960 | Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation |
| Q37288924 | Model-based analysis of interferon-beta induced signaling pathway. |
| Q90554819 | Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials |
| Q79750884 | Modification of TLR-induced activation of human dendritic cells by type I IFN: synergistic interaction with TLR4 but not TLR3 agonists |
| Q35084138 | Near eradication of clinically relevant concentrations of human tumor cells by interferon-activated monocytes in vitro |
| Q37800678 | New Pharmacologic Therapies in Chronic Hepatitis B |
| Q37390380 | Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients |
| Q39502676 | Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas |
| Q61738139 | Positive Selection of the Bat Interferon Alpha Gene Family |
| Q36305520 | Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors |
| Q37208454 | Potential role of type I interferons in the treatment of pituitary adenomas. |
| Q36880546 | Reduced interferon (IFN)-α conditioned by IFNA2 (-173) and IFNA8 (-884) haplotypes is associated with enhanced susceptibility to severe malarial anemia and longitudinal all-cause mortality |
| Q27478215 | Replicative Homeostasis III: implications for antiviral therapy and mechanisms of response and non-response |
| Q64273476 | Response of breast cancer cells to IFNα-2b in 2D and 3D cell cultures |
| Q42208901 | Role of A20 in interferon-α-mediated functional restoration of myeloid dendritic cells in patients with chronic hepatitis C. |
| Q21260407 | Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-beta |
| Q47132665 | Single-walled carbon nanotubes modulate pulmonary immune responses and increase pandemic influenza a virus titers in mice |
| Q86476480 | Space mutagenesis of genetically engineered bacteria expressing recombinant human interferon α1b and screening of higher yielding strains |
| Q34384616 | Structural analysis of cytokines comprising the IL-10 family |
| Q37852115 | The Chlamydia muridarum-Induced IFN-β Response Is TLR3-Dependent in Murine Oviduct Epithelial Cells |
| Q92879297 | The effects of IFITM1 and IFITM3 gene deletion on IFNγ stimulated protein synthesis |
| Q39515189 | The innate antiviral immune system of the cat: molecular tools for the measurement of its state of activation |
| Q38163987 | The molecular study of IFNβ pleiotropic roles in MS treatment |
| Q37053199 | The role of cytokines in the pathogenesis and treatment of HIV infection |
| Q38206556 | The role of interferon in the new era of hepatitis C treatments |
| Q36943194 | Two interferons alpha influence each other during their interaction with the extracellular domain of human type interferon receptor subunit 2 |
| Q38181142 | Type I Interferon at the Interface of Antiviral Immunity and Immune Regulation: The Curious Case of HIV-1. |
| Q37130475 | Type I interferons as vaccine adjuvants against infectious diseases and cancer |
| Q36892069 | Type I interferons induce autophagy in certain human cancer cell lines |
| Q56940144 | When Hepatitis B Virus Meets Interferons |
| Q58725930 | Who's Driving? Human Cytomegalovirus, Interferon, and NFκB Signaling |
| Q54160839 | [Alfa-interferons. Genetically engineered Antivirals]. |
Search more.